Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Iran J Pharm Res ; 18(2): 961-973, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31531077

RESUMEN

Streptokinase (SK) is an extracellular protein comprising 414 amino acids with considerable clinical importance as a commonly used thrombolytic agent. Due to its wide spread application and clinical importance designing more efficient SK production platforms worth investigation. In this regard, a synthetic SK gene was optimized and cloned in to pET21b plasmid for periplasmic expression. Response surface methodology was used to design a total of 20 experiments for optimization of IPTG concentration, post-induction period, and cell density of induction (OD600). The optimum levels of the selected parameters were successfully determined to be 0.28 mM for IPTG concentration, 9.889 H for post induction period, and 3.40768 for cell density (OD600). These settings result in 4.14fold increase in SK production rate of optimum expression conditions (7663 IU/mL) in comparison to the primary expression conditions (1853 IU/mL). Achieving higher yields of SK production in shake flask could lead to more cost effective industrial production of this drug which is the ultimate aim of SK production studies.

2.
Int J Biol Macromol ; 120(Pt B): 2448-2457, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30193917

RESUMEN

Type II l­asparaginase (l­ASNase) is an FDA approved enzyme drug with extensive applications for treatment of certain blood cancers. However, the therapeutic efficiency of this enzyme is hampered by its undesirable glutaminase activity. Given the pivotal role of this enzyme against cancer, designing engineered mutants with diminished glutaminase activity would be of great therapeutic interest. To this end, N248S mutation was selected as the potential mutation with beneficial effects. Various in silico analyses including MD simulation, molecular docking and QMMM studies were performed to assess the effects of N248S mutation on the activity of the enzyme. Thereafter, this mutation along with N248A, N248V and N248T mutations as controls were exerted in l­ASNase gene. The results from in silico analyses and experimental efforts indicated that N248S mutation is associated with the suitable l­ASNase activity, while the glutaminase activity is disturbed due to impaired interactions. It has been shown that glutamine turnover was affected much more strongly than asparagine hydrolysis. The approach of exploiting in silico tools to design mutated enzymes lead to staggering time and cost reduction. Following this strategy, we have designed a mutant l­ASNase with diminished glutaminase activity, which could be of interest for improved biomedical applications.


Asunto(s)
Asparaginasa/genética , Asparaginasa/metabolismo , Glutaminasa/metabolismo , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Mutación , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Secuencia de Aminoácidos , Sustitución de Aminoácidos , Asparaginasa/química , Asparaginasa/uso terapéutico , Dominio Catalítico , Estabilidad de Enzimas , Cinética , Mutagénesis Sitio-Dirigida , Teoría Cuántica
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...